Latest Dilution News

Capricorn Metals delivered a strong March quarter with rising gold output at Karlawinda, record operational cash flow, and significant progress on Mt Gibson development. The company also closed its gold hedging contracts, increasing exposure to gold price gains.

Loyal Lithium bolsters its North American lithium portfolio with significant exploration advances at Trieste and strategic board appointments, positioning itself strongly for the electric future.

Icon Energy Limited has received a Notice of Proposed Grant for Petroleum Lease PL-1144 in the Cooper Basin, marking a significant step toward resource development. Meanwhile, the company secured a $300,000 unsecured loan under revised terms, though its shares remain suspended pending native title negotiations and ASX approval.

Airtasker Limited has reported a robust 3Q25 with positive free cash flow and remarkable revenue growth in its UK and US marketplaces, signalling strong momentum in its international expansion.

CurveBeam AI Limited reported a $4.367 million net operating cash outflow for Q3 2025 but anticipates a significant improvement in cash flow driven by device installations and customer receipts, with no immediate plans for capital raising.

Horizon Minerals reported a significant A$7.48 million cash outflow for the March quarter, ending with just under A$6 million in cash and securing a US$5 million convertible loan to bolster liquidity.

Kuniko Limited has streamlined its Norwegian battery metals portfolio, pursued non-dilutive green funding, and forged AI satellite data partnerships, setting the stage for growth in Europe’s critical minerals sector.

GreenX Metals advances its Tannenberg Copper Project with BHP funding and license expansion, while Greenland projects gain momentum amid soaring antimony prices. The company also confirms a £435 million arbitration award against Poland, facing ongoing legal challenges.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

Thunderbird Resources has launched maiden exploration programs at its newly acquired NSW gold-antimony projects, uncovering promising historical high-grade assays and expanding its tenement holdings. Concurrently, the company advances copper exploration in Peru and contemplates uranium asset transactions in Canada.

Cavalier Resources has signed a non-binding US$11 million streaming finance term sheet with Raptor International to fund the Stage 1 open pit development of its Crawford Gold Project, backed by a robust updated Pre-Feasibility Study.